Neutralizing Antibodies to Interferon-β and other Immunological Treatments for Multiple Sclerosis

Deisenhammer, Florian
May 2009
CNS Drugs;2009, Vol. 23 Issue 5, p379
Academic Journal
Biopharmaceuticals can induce antibodies, which interact with and neutralize the therapeutic effect of such drugs and are therefore termed neutralizing antibodies (NAbs). In the treatment of multiple sclerosis, NAbs against interferon (IFN)-β and natalizumab have been recognized. The prevalence of NAbs against different IFNβ preparations varies widely, mainly depending on the product but also on other factors such as amino acid sequence variations, glycosylation, formulation, route and frequency of application, dose, duration of treatment and patient characteristics (human leukocyte antigen [HLA] status). IFNβ-1a given intramuscularly induces significantly less NAbs than any other IFNβ formulation. The longitudinal development of NAbs also differs between IFNβ preparations, with higher reversion rates in IFNβ-1b-treated compared with IFNβ-1a-treated patients. The negative effect of NAbs on various outcome measures is very consistent across many studies, specifically when observation periods are longer than 2 years. NAbs against natalizumab occur less frequently (6%)and, like NAbs against IFNβ, they are associated with a loss of clinical and radiological efficacy of the drug.


Related Articles

  • Escalating Immunotherapies for Highly Active Multiple Sclerosis: Reviewing the Evidence. Scalfari, Antonio; Nicholas, Richard; Malik, Omar; Muraro, Paolo A. // Current Medical Literature: Multiple Sclerosis;2010, Vol. 2 Issue 3, p61 

    The article discusses the immunotherapies for highly active multiple sclerosis (MS). It notes that glatiramer acetate (GA) or Interferon-beta can be used as the initial treatment in an escalating therapeutic strategy. It further states that monoclonal antibodies such as Natalizumab and...

  • "Neutralizing" Neutralizing Antibodies. de Myer, Desiree // BioPharm International;Jun2003, Vol. 16 Issue 6, p8 

    Discusses the effects of neutralizing antibodies on clinical efficacy of interferon betas which are used as effective therapies for multiple sclerosis. Relapse rate; Increase in disability progression; Multiple factors that can cause the development of antibodies.

  • IFN beta: Neutralizing antibodies.  // Multiple Sclerosis (13524585);Jan99 Supplement 1, Vol. 5 Issue 1, pS91 

    Presents summaries of several studies on interferon β. 'Neutralizing and Binding Anti-IFN- Β Antibodies: A Comparison Between IFN- Β 1a and -1b Treatment in Multiple Sclerosis,' by G. Alm, et al; 'A Study Comparing the Neutralizing Antibodies (Nab's) to Β Interferon in Patients...

  • Serum immunoglobulin levels in MS patients prescribed glatiramer acetate with or without pretreatment with an interferon-β in clinical practice.  // Canadian Journal of Neurological Sciences;May2003 Supplement 2, Vol. 30, pS29 

    Presents an abstract of the study 'Serum Immunoglobulin Levels in MS Patients Prescribed Glatiramer Acetate With or Without Pretreatment With an Interferon-beta in Clinical Practice' submitted to the 38th meeting of the Canadian Congress of Neurological Sciences.

  • Interferon-β in der Multiple-Sklerose-Therapie. Hartung, H.-P.; Haas, J.; Meergans, M.; Tracik, F.; Ortler, S. // Der Nervenarzt;Jun2013, Vol. 84 Issue 6, p679 

    The introduction of interferon-β in 1993 in the USA and 2 years later in Europe made it possible for the first time to alter the course of the disease in patients with relapsing-remitting multiple sclerosis (MS). Subsequently, interferon-β was approved for the treatment of patients with...

  • Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients. Weber, F; Cepok, S; Wolf, C; Berthele, A; Uhr, M; Bettecken, Th; Buck, D; Hartung, H P; Holsboer, F; Müller-Myhsok, B; Hemmer, B // Pharmacogenomics Journal;Jun2012, Vol. 12 Issue 3, p238 

    Interferons-β (IFN-β) are the most widely used immunomodulatory drugs for treatment of multiple sclerosis (MS). The development of neutralizing antibodies (NABs) against IFN-β is one of the main reasons for treatment failure. While formulation of the drug has a proven impact on the...

  • Interferons in Multiple Sclerosis: a single centre Indian experience. Salil, Gupta; Varadarajulu, R. // Annals of Indian Academy of Neurology;Nov2008 Supplement, Vol. 11, pS139 

    Introduction: The use of beta interferon to prevent relapse in multiple sclerosis (MS) has been established in RRMS and to a certain extent, in SPMS. We report a single centre Indian experience of patients with MS followed up for the last 3 years. Methods: Consecutive patients with suspected MS...

  • Glatiramer acetate triumphs in MS.  // PharmacoEconomics & Outcomes News;11/17/2007, Issue 541, p6 

    The article discusses the results of two studies on the cost effectiveness of a glatiramer acetate injection for the treatment of relapsing-remitting multiple sclerosis (MS). Researchers from the U.S. associate glatiramer acetate with lower odds of relapse and lower total direct medical costs...

  • Biogen and Abbott initiate enrollment in Phase III multiple sclerosis study.  // PharmaWatch: CNS;Jul2010, Vol. 9 Issue 7, p4 

    The article reports on the plan of Biogen Idec Inc. and Abbott Laboratories Inc. to initiate enrollment in a global Phase III multiple sclerosis (MS) study. It states that the study aims to evaluate the effectiveness and safety of daclizumab in treating patients with relapsing-remitting multiple...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics